公开(公告)号：US10787462B2

公开(公告)日：2020-09-29

申请号：US15769201

申请日：2016-10-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takatoshi Yogo ,  Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Katoh ,  Tomohiro Seki ,  Yoshihisa Nakada

IPC: C07D519/00 ,  C07D487/04 ,  C07D471/04 ,  C07D513/04 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P31/12 ,  A61P13/12 ,  A61P1/16 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like.The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US09828357B2

公开(公告)日：2017-11-28

申请号：US15356906

申请日：2016-11-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro ,  Taisuke Katoh ,  Masashi Yamasaki ,  Takahiro Tanaka ,  Naomi Kitamoto

IPC: C07D317/72 ,  C07C317/12 ,  C07D309/28 ,  C07C317/44 ,  C07C317/46

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.